Advertisement
Singapore markets closed

  • Straits Times Index

    3,280.10
    -7.65 (-0.23%)
     

  • Nikkei

    37,934.76
    +306.28 (+0.81%)
     

  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • Bitcoin USD

    63,134.04
    -1,189.98 (-1.85%)
     

  • CMC Crypto 200

    1,312.29
    -84.25 (-6.02%)
     

  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     

  • Dow

    38,239.66
    +153.86 (+0.40%)
     

  • Nasdaq

    15,927.90
    +316.14 (+2.03%)
     

  • Gold

    2,349.60
    +7.10 (+0.30%)
     

  • Crude Oil

    83.66
    +0.09 (+0.11%)
     

  • 10-Yr Bond

    4.6690
    -0.0370 (-0.79%)
     

  • FTSE Bursa Malaysia

    1,575.16
    +5.91 (+0.38%)
     

  • Jakarta Composite Index

    7,036.08
    -119.22 (-1.67%)
     

  • PSE Index

    6,628.75
    +53.87 (+0.82%)
     

SOPHiA GENETICS to Participate in Upcoming November Investor Conferences

SOPHiA GENETICS, Inc.
·1-min read

BOSTON and LAUSANNE, Switzerland, Oct. 28, 2021 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH) today announced the company will be participating virtually in the following investor conferences:

  • Credit Suisse 30th Annual Healthcare Conference; Fireside Chat on Thursday, November 11th at 2:40pm ET / 8:40pm CET

  • Piper Sandler 33rd Annual Healthcare Conference; Presentation available on demand beginning November 22nd at 10:00am ET / 4:00pm CET

  • Evercore ISI HealthCONx Conference; Fireside Chat on Tuesday, November 30th at 8:00am ET / 2:00pm CET

Interested parties may access live and archived webcasts of the presentations on the “Investors” section of the company website at ir.sophiagenetics.com.

About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by more than 780 hospital, laboratory, and biopharma institutions globally.

Media Contact:
Eliza Bamonti
ebamonti@sophiagenetics.com

Investor Contact:
ir@sophiagenetics.com